{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-029009","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.243148+00:00","generated_at":"2026-05-26T01:58:28.281490+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Treace Medical Q4 revenue $68.7M (+10% YoY); net loss narrows to $0.5M; guides FY25 rev $224-230M","bullets":["Q4 revenue $68.7M (+10% YoY); net loss ($0.5M) vs ($6.3M) in Q4 2023; adj. EBITDA $11.1M (322% improvement).","Full-year 2024 revenue $209.4M (+12% YoY); net loss ($55.7M) vs ($49.5M); adj. EBITDA loss narrowed to ($11.0M) from ($24.4M).","FY2025 revenue guidance $224M-$230M (7-10% growth); expects breakeven adj. EBITDA for full year.","Entry into osteotomy market with Nanoplasty and Percuplasty 3D bunion systems; 280 new active surgeons added in 2024.","Cash $75.7M plus $26M revolver access; patent portfolio 97 granted, 88 pending."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-029009","json":"https://secwatch.observer/filing/0000950170-25-029009.json","markdown":"https://secwatch.observer/filing/0000950170-25-029009.md","text":"https://secwatch.observer/filing/0000950170-25-029009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025029009/0000950170-25-029009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025029009/tmci-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:58:28.281490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}